Dynamic Advisor Solutions LLC cut its holdings in CVS Health Co. (NYSE:CVS) by 1.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,008 shares of the pharmacy operator’s stock after selling 619 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in CVS Health were worth $3,505,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the stock. Brighton Jones LLC boosted its stake in shares of CVS Health by 3.7% in the second quarter. Brighton Jones LLC now owns 13,661 shares of the pharmacy operator’s stock valued at $1,140,000 after buying an additional 490 shares in the last quarter. Wakefield Asset Management LLLP purchased a new stake in shares of CVS Health in the second quarter valued at approximately $253,000. CapWealth Advisors LLC boosted its stake in shares of CVS Health by 3.7% in the second quarter. CapWealth Advisors LLC now owns 292,140 shares of the pharmacy operator’s stock valued at $24,376,000 after buying an additional 10,310 shares in the last quarter. River Road Asset Management LLC boosted its stake in shares of CVS Health by 589.9% in the second quarter. River Road Asset Management LLC now owns 398,320 shares of the pharmacy operator’s stock valued at $33,236,000 after buying an additional 340,587 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV boosted its stake in shares of CVS Health by 32.0% in the second quarter. Mercer Global Advisors Inc. ADV now owns 196,959 shares of the pharmacy operator’s stock valued at $16,434,000 after buying an additional 47,797 shares in the last quarter. Hedge funds and other institutional investors own 75.94% of the company’s stock.
CVS Health stock traded up $1.12 during trading on Wednesday, hitting $85.01. The company’s stock had a trading volume of 183,455 shares, compared to its average volume of 6,445,591. The stock has a market capitalization of $112.18 billion, a price-to-earnings ratio of 15.39, a P/E/G ratio of 1.68 and a beta of 0.83. The stock’s fifty day moving average is $83.62 and its 200 day moving average is $81.03. CVS Health Co. has a 1-year low of $55.36 and a 1-year high of $90.61. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.67 and a current ratio of 0.95.
The company also recently declared a quarterly dividend, which was paid on Monday, August 2nd. Shareholders of record on Friday, July 23rd were paid a dividend of $0.50 per share. The ex-dividend date of this dividend was Thursday, July 22nd. This represents a $2.00 annualized dividend and a yield of 2.35%. CVS Health’s dividend payout ratio is presently 26.67%.
In other CVS Health news, EVP Alan Lotvin sold 2,781 shares of the company’s stock in a transaction dated Monday, June 28th. The stock was sold at an average price of $83.67, for a total transaction of $232,686.27. Following the completion of the sale, the executive vice president now directly owns 61,048 shares in the company, valued at $5,107,886.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig purchased 3,000 shares of the company’s stock in a transaction on Thursday, August 5th. The shares were purchased at an average price of $79.55 per share, with a total value of $238,650.00. Following the completion of the purchase, the director now directly owns 17,334 shares of the company’s stock, valued at $1,378,919.70. The disclosure for this purchase can be found here. Corporate insiders own 0.69% of the company’s stock.
CVS has been the topic of a number of analyst reports. Morgan Stanley lifted their price target on CVS Health from $99.00 to $114.00 and gave the company an “overweight” rating in a research note on Tuesday, August 31st. Deutsche Bank Aktiengesellschaft boosted their target price on CVS Health from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, August 5th. Barclays boosted their target price on CVS Health from $92.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 19th. BMO Capital Markets boosted their target price on CVS Health from $90.00 to $96.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 19th. Finally, Tigress Financial reiterated a “buy” rating and set a $108.00 target price on shares of CVS Health in a research report on Friday, July 23rd. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $94.89.
CVS Health Profile
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits, and Corporate/Other. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise.
Further Reading: How to Trade Using Analysts Ratings
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.